EMA Application withdrawn: Fingolimod Mylan (fingolimod hydrochloride) — Mylan Ireland Limited

View source ↗

Summary

The EMA withdrew the application for Fingolimod Mylan (fingolimod hydrochloride) from consideration for relapsing-remitting multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• Fingolimod Mylan (Fingolimod)

Snippet

Status: Application withdrawn. Therapeutic area: Multiple Sclerosis, Relapsing-Remitting. MAH: Mylan Ireland Limited. Decision date: 28/04/2023